摘要
目前肥胖症治疗方法包括生活方式干预、药物治疗和减重代谢手术,但非手术策略难以使大多数患者体重持续下降。新兴的GLP-1受体激动剂(GLP-1RAs)司美格鲁肽作为一种得到证实的对肥胖症以及糖尿病等疾病具有良好治疗效果的药物,通过激活下丘脑内的GLP-1受体,调节食欲并延迟肠胃排空。但其不良反应包括低血糖、胆石症、急性胰腺炎、自伤及自杀风险增高等,现已均有报道。未来研究应进一步涵盖更多元化的人群,并开展针对中国人群的大型随机对照试验以更好地完善临床应用。本文总结了司美格鲁肽在肥胖症慢性体重管理中的作用机制、体重减轻疗效及安全性。
Current treatments for obesity include lifestyle interventions,pharmacotherapy,and bariatric metabolic surgery.However,non-surgical strategies often fail to sustain weight loss for most patients.The emerging glucagon-like peptide 1 receptor agonists(GLP-1RAs),semaglutide,has been proven effective in treating obesity and diseases such as diabetes.It works by activating GLP-1 receptors in the hypothalamus,regulating appetite,and delaying gastric emptying.However,adverse effects such as hypoglycemia,cholelithiasis,acute pancreatitis,and increased risks of self-harm and suicide have been reported.Future research should include more diverse populations and conduct large-scale randomized controlled trials targeting the Chinese population to better refine clinical applications.This review summarizes the mechanisms,weight loss efficacy,and safety of semaglutide in chronic weight management for obesity.
作者
颜宥彤
赵锐
万谦益
张贵祥
沈弘毅
程中
陈亿
Zhao Rui;WanQianyi;Zhang Guixiang;Shen Hongyi;Cheng Zhong;Chen Yi(Bariatic Surgery Center,Department of Gastrointestinal Surgery,West China Hospital,Sichuan University,Chengdu 610041,China)
出处
《中华肥胖与代谢病电子杂志》
2024年第2期88-93,共6页
Chinese Journal Of Obesity and Metabolic Diseases：Electronic Edition
作者简介
通信作者:陈亿,Email:toddy@scu.edu.cn,博士,教授,博士生导师,四川大学华西医院院感部部长。中国医师协外科医师分会肥胖和糖尿病外科全国青年委员,国际肥胖与代谢病外科联盟会员,美国肥胖代谢外科学院国际会员,四川省国际医学交流促进会肥胖和糖尿病外科专业委员会主任委员,四川省预防医学会肥胖防治分会副主任委员,全球EMT救援队队员。主持2项国家级项目、2项省部级项目,获四川省卫健委学术技术带头人后备人选称号。参与援非圣多美和普林西比医疗队并担任队长,开展了包括结直肠癌根治术在内的多项外科手术。荣获2021年四川省卫健委、四川省援外医疗工作先进个人奖以及四川省援外医疗工作先进集体称号
